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Propylthiouracil (PTU) and methimazole (MMI) are the most commonly used antithyroid drugs. The available data suggest that
these drugs may block the thyroid hormone synthesis by inhibiting the thyroid peroxidase (TPO) or diverting oxidized iodides
away from thyroglobulin. It is also known that PTU inhibits the selenocysteine-containing enzyme ID-1 by reacting with the se-
lenenyl iodide intermediate (E-SeI). In view of the current interest in antithyroid drugs, we have recently carried out biomimetic
studies to understand the mechanism by which the antithyroid drugs inhibit the thyroid hormone synthesis and found that the
replacement of sulfur with selenium in MMI leads to an interesting compound that may reversibly block the thyroid hormone
synthesis. Our recent results on the inhibition of lactoperoxidase (LPO)-catalyzed oxidation and iodination reactions by antithy-
roid drugs are described.
Copyright © 2006 G. Roy and G. Mugesh. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Thyroxine or 3,3
￿,5,5
￿-tetraiodothyronine (T4) is the major
hormone secreted by the follicular cells of the thyroid gland.
This hormone is produced on thyroglobulin by thyroid per-
oxidase (TPO)/hydrogen peroxide/iodide system. The syn-
thesis of T4 by TPO involves two independent steps: iod-
ination of tyrosine and phenolic coupling of the resulting
iodotyrosine residues [1–5]. The prohormone T4 is then
converted to its biologically active form T3 by an outer ring
deiodination pathway. This particular reaction is catalyzed
by a selenocysteine-containing enzyme called iodothyronine
deiodinase (ID-I), which is present in highest amounts in
liver,kidney,thyroid,andpituitary[6–16].Thethyroidgland
also produces an inactive metabolite rT3 by an inner ring
deiodination pathway. The triiodo derivatives T3 and rT3
are further metabolized by inner ring and outer ring deio-
dination, respectively, by ID-I, ID-II, and ID-III to produce
the inactive metaboilite T2 (3,3
￿- T2, 3,5- T2, and 3
￿,5
￿-T 2 ) .
The outer ring 5
￿-deiodination catalyzed by the ID-I enzyme
is considered to be the ﬁrst step in thyroid hormone ac-
tion because this is the only deiodination pathway that leads
to the formation of an active thyroid hormone. It is now
widely accepted that the deiodination catalyzed by ID-I is
a ping-pong, bisubstrate reaction in which the selenol (or
selenolate) group of the enzyme (E-SeH or E-Se
￿)ﬁ r s tr e -
acts with thyroxine (T4) to form a selenenyl iodide (E-SeI)
intermediate. Subsequent reaction of the selenenyl iodide in-
termediate with an as yet unidentiﬁed intracellular cofactor
completes the catalytic cycle and regenerates the enzyme ac-
tive site (Figure 1)[ 8, 14]. Although it is customary to use
dithiothreitol (DTT, 1,4-dithiothreitol, Cleland’s reagent)a s
the second substrate in in vitro experiments, the identity
of the physiological second substrate is still uncertain. The
tripeptide glutathione (GSH) can also act as a thiol cosub-
strate, but GSH is a much less potent cofactor than DTT for
ID-I [10, 17]. In addition to GSH, other native thiols such as
dihydrolipoic acid or dihydrolipoamide may serve as cofac-
tors for ID-I [17, 18]. Therefore, Figure 1 may be an incom-
plete or incorrect representation of the catalytic mechanism
of ID-I since evidence for the cofactor systems mentioned
above has only been presented for in vitro studies and not
for in vivo analysis.
Although the deiodination reactions are essential for the
function of thyroid gland, the activation of thyroid stimu-
lating hormone (TSH) receptor by autoantibodies leads to
an overproduction of thyroid hormones. As these antibod-
ies are not under pituitary feedback control system, there
is no negative inﬂuence on the thyroid activity and, there-
fore, the uncontrolled production of thyroid hormones leads2 Bioinorganic Chemistry and Applications
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Figure 1: Proposed mechanism for the deiodination of thyroxine by ID-I and inhibition of ID-I by n-propyl-2-thiouracil (PTU) and gold
thioglucose (GTG).
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Figure 2: Chemical structures of some commonly employed an-
tithyroid drugs and their selenium analogues.
to a condition called “hyperthyroidism.” The overproduc-
tion of T4 and T3 can be controlled by blocking the thyroid
hormone biosynthesis or reducing the conversion of T4 to
T3. The thiourea drugs such as methimazole (1, MMI), 6-n-
propyl-2-thiouracil (3, PTU), and 6-methyl-2-thiouracil (5,
MTU) are generally employed for this purpose (Figure 2).
Despite the importance of these antithyroid drugs in the
treatment of hyperthyroidism, the detailed mechanism of
their action is still not clear. According to the initially pro-
posed mechanism, these drugs may divert oxidized iodides
away from thyroglobulin by forming stable electron donor-
acceptor complexes with diiodine, which can eﬀectively re-
duce the thyroid hormone biosynthesis [19, 20]. It has also
been proposed that these drugs may block the thyroid hor-
monesynthesisbycoordinatingtothemetalcenterofthyroid
peroxidase (TPO) [21]. After the discovery that the ID-I is
responsible for the activation of thyroxine, it has been re-
ported that PTU, but not MMI, reacts with the selenenyl io-
dide intermediate (E-SeI) of ID-I to form a selenenyl sulﬁde
as a dead end product, thereby blocking the conversion of
T4 to T3 during the monodeiodination reaction (Figure 1)
[8, 14, 22–24]. The mechanism of antithyroid activity is fur-
ther complicated by the fact that the gold-containing drugs
such as gold thioglucose (GTG) inhibits the deiodinases by
reacting with the selenol (or selenolate) group of the native
enzyme (Figure 1)[ 8, 24].
In recent years, the selenium analogues 2 (MSeI), 4
(PSeU), and 6 (MSeU) attracted considerable attention be-
cause these compounds are expected to be more nucle-
ophilic than their sulfur analogues and the formation of an
￿Se
￿Se
￿ bond may occur more readily than the formation
of an
￿Se
￿S
￿ bond with the ID-I enzyme [25–29]. How-
ever, the data derived from the inhibition of TPO by sele-
nium compounds show that these compounds may inhibit
t h eT P Oa c t i v i t yb yad i ﬀerent mechanism. We have recently
shown that the unexpected behavior of the selenium com-
pound MSeI as compared to that of its sulfur analogue may
be due to the existence of this compound in the zwitterionic
form and its facile oxidation to the corresponding diselenide
(8) [30, 31]. In this paper, we summarize our recent results
on the eﬀect of antithyroid drugs on peroxide-catalyzed ox-
idation and iodination reactions. In addition, we show that
the replacement of sulfur with selenium in MMI leads to an
interesting compound (MSeI) that exhibits signiﬁcant glu-
tathione peroxidase (GPx)-like antioxidant activity.
INHIBITION OF LACTOPEROXIDASE-CATALYZED
OXIDATION BY ANTITHYROID DRUGS
The eﬀect of antithyroid drugs on peroxidase-catalyzed
oxidation was studied in vitro by using spectroscopicG. Roy and G. Mugesh 3
Table 1: Inhibition of LPO activity by 1–3, and 5 [31].
No Compound IC50 (μM)a
1 MMI (1) 7.0
￿1.1
2 MSeI (2) 16.4
￿1.5
3 PTU (3) 45.0
￿2.1
4 MTU (5) 47.8
￿0.1
a Concentration of the compound causing 50% inhibition. Each IC50 value
was calculated from at least three independent experiments.
techniques. The enzyme inhibition experiments were car-
ried out with iron-containing lactoperoxidase (LPO) since it
is readily available in puriﬁed form. Furthermore, LPO has
been shown to behave very similarly to TPO with respect to
oxidation of organic substrates and iodination of thyroglob-
ulinandotheriodide acceptors[32].Wehaveemployed2,2
￿-
azio-bis-3-ethyl-benthiazoline-6-sulfonic acid (ABTS) and
H2O2 as substrates [33] to determine the half-maximal in-
hibitory concentration (IC50) of test compounds. The IC50
valuesforthe inhibition ofLPO-catalyzedoxidation ofABTS
by 1–3 and 5 are summarized in Table 1 [31]. The sulfur
compound MMI inhibited the LPO activity with an IC50
value of 7.0
￿ 1.1μM, which is much lower than those ob-
served with PTU and MTU. The selenium analogue (2) also
inhibited LPO activity and the IC50 value was found to be
almost 2-3 times lower than those of PTU and MTU. The
higher activity of MMI as compared with those of PTU and
MTU is in agreement with the previous studies on the in-
hibition of TPO. Since the activation of the iron center in
TPO must proceed through an interaction of Fe(III) with
H2O2, TPO inactivation may occur through a competitive
coordination of the drug to iron, assisted by hydrogen bond-
ing with a histidine residue of the TPO enzyme [34]. Un-
der these conditions, MMI might compete more successfully
than PTU with H2O2 because the hydrogen-bond (hard) ba-
sicity pkHB value of MMI (2.11) is much higher than that of
PTU (∼ 1.32). Similarly to PTU, the methyl derivative 5 is
also expected to be a weak inhibitor of TPO. On the other
hand, compound 2, which exists predominantly in the zwit-
terionic form (Scheme 1)[ 35], probably does not have the
ability to coordinate to the iron center; therefore, this com-
pound may inhibit the LPO activity by a diﬀerent mecha-
nism. Although the zwitterionic selenolate can be oxidized
in solution to give the corresponding diselenide (8), the ob-
served inhibitory activity must be ascribed entirely to the
presence of the reduced form (2) as the oxidized compound
(8) does not show any noticeable inhibition behavior under
identical experimental conditions.
Taurog et al have shown that MMI and related deriva-
tives irreversibly inhibit LPO and TPO, leading to a com-
pleteinactivationoftheenzymes[36–39].Doergeandothers
haveshownthatmammalianperoxidasesincludingLPOmay
activate the antithyroid drugs through S-oxygenation to pro-
duce the corresponding sulfoxides or sulﬁnic acids [40, 41].
They have also shown that the suicide inactivation of LPO
andTPObyMMIproceedsthroughtheS-oxygenationofthe
thione moiety to form a reactive sulﬁnic acid, which binds
HN
Se
NM e
(2a)
N
SeH
NM e
(2b)
HN
Se
NM e +
￿
(2c)
Scheme 1: The possible tautomeric structures of compound 2. The
compound exists predominantly in its zwitterionic form 2c, which
may have a partial C
￿Se double bond character.
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Figure3:Plotofinitialrates(vo)fortheLPO-catalyzedoxidationof
ABTS versus concentration of H2O2: (a) control activity; (b) 40μM
of2;(c)40μMof8;(d)80μMofPTU;(e)80μMofMTU;(f)40μM
of MMI. Conditions: LPO: 6.5nM; H2O2: 22.9μM( s e e[ 31]).
covalently to the prosthetic heme and irreversibly blocks en-
zyme activity [42–45]. Given the higher reactivity of sele-
nium compounds as compared with the sulfur derivatives
toward oxidation, it is possible that the facile oxidation of
the selenium compounds may lead to an eﬃcient inhibition
of LPO activity. With this in mind, we treated MMI, PTU,
M T U ,a n dM S e Iw i t hH 2O2 before adding LPO and ABTS.
The LPO activity was measured several times by increasing
the time for the reaction of the test compounds with H2O2.
Remarkably, MSeI (2) inhibited the enzyme within few sec-
onds even at lower concentrations, which can be ascribed
to the facile oxidation of the reactive selenolate group in 2
(MSeI) by H2O2 or by the oxidized enzyme. Because MMI
also inhibits the enzyme very eﬃciently, we have carried out
further experiments to prove that the mechanisms by which
MMI and MSeI exert their inhibitory action are diﬀerent.
The initial rates (v0) derived from various concentrations of
H2O2 were plotted against the concentration of H2O2.T h e
LPO activity was completely inhibited by 40μMM M I ,a n d
the enzyme’s activity could not be recovered by increasing
the H2O2 concentration (Figure 3f) [31]. The LPO activity
could not be recovered even at lower concentration of MMI
(10μM) and higher concentration of H2O2 (230μM). This4 Bioinorganic Chemistry and Applications
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suggests that MMI does not act on H2O2 b u ta c t so nt h ee n -
zyme itself, leading to an irreversible inhibition as previously
proposed. On the other hand, 2 also inhibited the LPO activ-
ity as eﬃciently as MMI, but in this case, the enzyme’s activ-
ity could be completely recovered by increasing H2O2 con-
centration (Figure 3b). These observations may support the
assumption that MSeI, in contrast to MMI, does not inter-
fere with the native enzyme directly but it inhibits the LPO
activity by reducing the H2O2, which is required for the oxi-
dation of the iron center in LPO. The reduction of H2O2 by 2
may become more eﬃcient in the presence of suitable thiols
such as GSH because this process may constitute a redox cy-
cle involving a catalytic reduction of H2O2 (glutathione per-
oxidase (GPx) activity) [46]. Thus, compound 2 mimics the
actionofGPx,aselenoenzymethatprotectsthecellularcom-
ponents from oxidative damage by reducing H2O2 with the
help of GSH [16]. Recently, the GPx enzyme present in thy-
roidglandhasbeenshowntoinhibittheiodinationreactions
by degrading the intracellular H2O2 [47, 48]. The high GPx
activity of the key compound 2 leads to an assumption that
the antithyroid drugs may act as antioxidants in addition to
their inhibition behavior.
INHIBITION OF LACTOPEROXIDASE-CATALYZED
IODINATION BY ANTITHYROID DRUGS
The interesting results that we obtained from the inhibition
of LPO-catalyzed oxidation reactions by MSeI (2) prompted
us to study the eﬀect of this compound and related deriva-
tives on the LPO-catalyzed iodination reactions [49]. In ad-
dition, we have studied the reactivity of MSeI toward iodine
because the eﬀect of the selenium compounds on the io-
dination of tyrosine and the identiﬁcation of the products
formed in the reactions of these compounds with iodine are
crucial in understanding the mechanism of action in vivo of
these drugs. The iodination of tyrosine was studied by using
LPO/H2O2/I
￿ assay and the initial rates for the conversion of
L-tyrosine to 3-iodo L-tyrosine (Scheme 2) were determined
by an HPLC method.
As the formation of 3,5-diiodo-L-tyrosine was also ob-
served in the reaction, only the initial 5%–10% of the con-
version was followed where only a trace amount of the di-
iodo compound was produced. The decrease in the concen-
tration of L-tyrosine was followed by measuring the peak
area at 277nm and the amount of tyrosine present in the so-
lutionatagiventimewascalculatedfromthecalibrationplot
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Figure 4: Inhibition of the LPO-catalyzed iodination of L-tyrosine
by MSeI. The decrease in the amount of tyrosine with time was fol-
lowed by HPLC: (a) control; (b) 6μMo f2 ;( c )9μMo f2 ;( d )1 2μM
of 2; (d) 15μMo f2 ;a n d( e )2 0μMo f2( s e e[ 49]).
obtained by injecting known concentrations of L-tyrosine.
The eﬀect of compound 2 on the iodination reaction was de-
termined at various concentrations of 2 under identical ex-
perimental conditions (Figure 4). The incubation mixtures
for the HPLC analysis contained KI, L-tyrosine, hydrogen
peroxide, and LPO enzyme. The mixture was incubated in
phosphate buﬀer at room temperature and aliquots were in-
jected onto the HPLC column and eluted with gradient sol-
vent system (0.1% TFA in water-MeCN). The decrease in
the amount of tyrosine (μg) was calculated from the cali-
bration plot. The concentration of compound 2 was varied
from 6μMt o2 0 μM, and a signiﬁcant inhibition was ob-
served even at the lowest concentration of 2.
To understand the eﬀect of peroxide substrate on the re-
action rate and the inhibition, the LPO activity was deter-
mined at various concentrations of hydrogen peroxide. In
addition, the eﬀect of peroxide on the inhibition of LPO-
catalyzed iodination by antithyroid drugs 1 and 2 was eval-
uated by carrying out the experiments at various concentra-
tions of H2O2. In this HPLC assay, the incubation mixtures
containing KI, L-tyrosine, LPO enzyme, and various concen-
trations of hydrogen peroxide were incubated at room tem-
perature. The aliquots were removed from the reaction mix-
ture at various time intervals, injected onto the HPLC col-
umn and eluted with gradient solvent system (0.1% TFA in
water-MeCN). The formation of monoiodo tyrosine was fol-
lowed at 295nm. The initial rates (v0)d e r i v e df o rv a r i o u s
concentrations of H2O2 were plotted against the concentra-
tion of H2O2. Although the LPO activity was inhibited by 2
at lower concentrations of H2O2, the enzyme’s activity could
be completely recovered by increasing H2O2 concentration
(Figure 5). These results suggest that the concentration of
H2O2 has a dramatic eﬀect on the inhibition of iodination
reaction by compound 2 (Figure 5)[ 49].G. Roy and G. Mugesh 5
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Figure 5: Inhibition of the LPO-catalyzed iodination of L-tyrosine
by MSeI. EﬀectofH2O2 on the inhibition by 2; (a) 0μM;(b)20μM;
(c) 30μM; (d) 40μM; inset: inhibition of tyrosine iodination by (e)
1; (f) 2 at a ﬁxed H2O2 concentration.
The IC50 values for the inhibition of LPO-catalyzed
iodination of L-tyrosine by the test compounds were also
determined by following the same procedure. The initial
rates for the iodination reaction were determined at various
concentrations of inhibitors. The inhibition curves obtained
by plotting the percentage control activity against the con-
centration of inhibitors are shown in Figure 5 (inset). As ex-
pected, MMIexhibited a stronginhibition withanIC50 value
of 5.2μM, which is comparable with the IC50 value obtained
for the LPO-catalyzed oxidation reaction [30, 31]. The sele-
nium analogue (2) also showed a strong inhibition with an
IC50 value of 12.4μM, which is consistent with the eﬀect of
this compound on peroxidase-catalyzed oxidation reactions
[30, 31]. Similarly to the LPO-catalyzed oxidation of 2,2
￿-
azino-bis-3-ethylbenz-thiazoline sulfonic acid (ABTS), this
suggests that the selenium analogue may inhibit the LPO by
ad i ﬀerent mechanism. The diselenide 8, on the other hand,
did not show any noticeable inhibition under identical con-
ditions. This conﬁrms that the reduction of the diselenide to
the corresponding selenolate is essential for an eﬃcient inhi-
bition of LPO-catalyzed oxidation or iodination reactions.
INTERACTION OF ANTITHYROID DRUGS WITH IODINE
The nature of charge-transfer complexes between hetero-
cyclic antithyroid drugs and diiodine is an important area of
interest in the study of hyperthyroidism [50], and the elec-
trical properties in general and the superconducting ability,
in particular, of sulfur-iodine complexes are also of current
interest [51–54]. Recently, a great deal of eﬀort has been de-
voted to the understanding of the interaction of antithyroid
drugswithiodine[55–59].Thesestudiesmayprovideinsight
into the nature of products formed during the inhibition
of thyroid hormone synthesis. As mentioned in the intro-
duction, it has been proposed that these drugs may divert
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Figure 6:Chemicalstructuresofcompounds9and10derivedfrom
the compound 2.
oxidized iodides away from thyroglobulin by forming stable
electron donor-acceptor complexes with diiodine, which can
eﬀectively reduce the thyroid hormone biosynthesis [19, 20].
BecausetheoxidationofMMItothecorrespondingdisulﬁde
(7)byTPO/H2O2/I
￿ systemisassociatedwiththereactionof
MMI with I2 [55–59], we have investigated the interaction of
2 and 8 with iodine. It has been reported that I2 chemically
oxidizes MMI to produce ionic disulﬁdes that exist in two
diﬀerent protonated forms [55]. It is unknown whether the
selenium analogue of MMI, in its reduced form, also under-
goes such oxidation by I2 to produce ionic species (Figure 6).
Therefore, we carried out the experiments with the reduced
species (2), which exists in its zwitterionic form [31, 35]. The
reaction of 2 with I2 in CH2Cl2 producedred-brown crystals.
Interestingly, the X-ray crystal structureshows the formation
of compound 9, which consists of a monocation containing
a diselenide and I3
￿ as counterion (Figure 7)[ 49]. This is in
contrast to the reaction of MMI with I2 in CH2Cl2, which af-
fordedadisulﬁde-containingdicationandI8
￿ ascounterions
[55].
The formation of the monocationic species 9 is inter-
esting from a chemical point of view as only one of the
imidazole rings undergoes oxidation. It should be men-
tioned that the N-methylation on MMI has been shown
to abolish its TPO inhibitory activity [60]. Freeman et al
have shown that the reaction of the N-methylated derivative
(1,3-dimethylimidazole-2-thione) with I2 does not produce
any disulﬁde, but it produces a 1 : 1 thione : I2 charge-
transfer adduct [61]. The N-methylated derivative of 2 (1,3-
dimethylimidazole-2-selone), on the other hand, produces a
hypervalent “T-shaped” compound having I
￿Se
￿Im o i e t y
[62, 63]. It should be noted that the reaction of the methy-
lated analogue of 2, 1,3-dimethylimidazole-2-selone, with
one equivalent bromine aﬀords a hypervalent compound
having Br
￿Se
￿Br moiety, whereas the corresponding reac-
tion utilizing a half-equivalent bromine leads to the forma-
tion of a diselenide dication having two Br
￿ as counterions
[64]. Therefore, the existence of 2 in its zwitterionic (or se-
lenolate) form is probably responsible for its diﬀerent reac-
tivity toward iodine. Stable open-chain cationic diselenide
species are very uncommon in the literature and to the best
of our knowledge no structural information is available for
complexes derived from the reactions of selenium analogues
ofantithyroiddrugswithiodine.Thechemicaloxidationof2
by I2 suggests that compound 8, which exists in the oxidized
form of 2, may not produce any ionic species. To test this,
the diselenide 8 was treated with I2 in a 1 : 2 molar ratio in
CH2Cl2.6 Bioinorganic Chemistry and Applications
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Figure 7: Molecular structures of (a) monocation 9 showing the
hydrogen bonding between two monocations and (b) dication 10
[49].
This reaction yielded a brown solution from which dark-
brown crystals were obtained on standing at room tempera-
ture. Surprisingly, the X-ray crystal structure shows the for-
mation of a monocationic species, which is identical with
that obtained from the reaction of 2 with I2 (Figure 7). The
formation of a cationic species in this reaction is quite un-
expected because the reactions of iodine with diselenides
generally produce selenenyl iodide species or charge-transfer
complexes having diselenide-molecular iodine adducts [65].
It is also known that some of the selenenyl iodides may
undergo disproportionation to give diselenide-iodine com-
plexes.
The far-IR spectrum of complex 9 shows a distinct band
at 135cm
￿1 for the ν(I
￿I) stretching vibration mode. This
300 250 200 150 100 50
276
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200
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110
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¯ ν (cm
￿1)
Figure 8: FT-Raman spectra of the monocation 9 (a), diselenide 8
(b), and the dication 10 (c) (see [49]).
is in agreement with the fact that I2 gives a strong band at
180cm
￿1 in the solid state, which shifts to lower wavenum-
bers upon coordination to a donor atom, reﬂecting a re-
duction in the I
￿Ib o n do r d e r[ 56]. The FT-Raman spec-
trum of the complex in the ν(I
￿I) region shows intense
peaks at 164cm
￿1, 143cm
￿1, and 110cm
￿1. In addition, a
weak band is observed around 67cm
￿1 (Figure 8). The band
at 110cm
￿1 can be certainly assigned to the ν1 symmetric
stretchingofI3
￿,whichbeingasymmetricalionnormallyex-
hibits only one Raman active band. However, when a distor-
tion of I3
￿ occurs, the antisymmetric stretching may become
Raman active and additional bands at higher (140cm
￿1–
130cm
￿1) and at lower frequencies (80cm
￿1–70cm
￿1)m a y
be observed [56, 66]. Therefore, the relatively weak bands at
143cm
￿1 and 67cm
￿1 can be attributed to the antisymmet-
ric stretching and deformation motions, respectively, for the
I3
￿ ion (Figure 8a).
The single crystal X-ray studies conﬁrm the proposed
structure of 9 (Figure 7), which consists of two independent
diselenidemonocations[Se
￿Se:2.382 ˚ A;2.364 ˚ A].Thesedis-
elenide cations interact with their symmetry equivalents
through N
￿H
￿
￿
￿N hydrogen bonds to form dimeric units
with overall charge 2+. The charge balance in the crystals is
achieved by the presence of two I3
￿ anions. The two C
￿Se
bond lengths in each subunit are unequal due to the mono-
protonation of the one of the ﬁve-membered rings [C
￿Se:
1.886–1.890 ˚ A]. The I
￿I bond lengths observed also diﬀer
signiﬁcantly from the corresponding I
￿Ib o n dl e n g t ho fI 2
in the solid state (2.715 ˚ A). The two I
￿I bond lengths of the
I3
￿ species in complex 9 range from 2.888 ˚ A to 2.919 ˚ A, indi-
cating a slight distortion of the I3
￿ moiety. This distortion is
probably responsible for additional bands in the FT-Raman
spectrum of the complex.
In the reaction between 8 and I2 in dichloromethane,
the concentrations of I2 do not appear to change the na-
ture of products. During our attempts to oxidize the secondG. Roy and G. Mugesh 7
ring using various concentrations of I2 up to an excess, only
the monocation was obtained as a stable product. However,
the choice of solvent has been found to have a large inﬂu-
ence on the nature of products formed. The reaction of 8
with I2 in a 1 : 2 molar ratio in water produced a mixture
containing both monocation (9) and dication (10) as con-
ﬁrmed by single-crystal X-ray studies (Figure 7). In contrast
to the monocation, the charge balance in the crystal of dica-
tion is achieved by two I
￿ anions. In compound 10, the aver-
age C
￿Se bond length of 1.895 ˚ Ai sc o m p a r a b l ew i t ht h a to f
the diselenide 8 (1.880 ˚ A) [30], but this is signiﬁcantly longer
than the average C
￿Se bond length (1.848 ˚ A) found in com-
pound 2 that exists in a zwitterionic form [35]. As expected,
the FT-Raman spectrum of compound 10 shows no peaks in
the region of lower wavenumbers (Figure 8c), indicating the
absence of any polyiodide species in the crystals.
CONCLUSIONAND OUTLOOK
Ourrecentresultsshowthattheseleniumanalogueofmethi-
mazole (MSeI) exists predominantly in its zwitterionic form,
in which the selenium atom carries a negative charge and
theﬁve-memberedheterocyclicringcarriesapositivecharge.
In contrast to the sulfur analogue, the zwitterionic form of
MSeIisunstableandoxidizes inairtothecorresponding dis-
elenide. The resulting diselenide can be easily reduced by re-
ducing agents such as NaBH4 or glutathione (GSH). In its
reduced form (zwitterionic or selenolate), MSeI eﬀectively
and reversibly inhibits the lactoperoxidase (LPO)-catalyzed
oxidation reactions. These results suggest that MSeI may not
interfere with the native enzyme directly, but it may inhibit
LPO either by reducing the H2O2 that is required for the ox-
idation of the iron center in LPO or by interfering with the
oxidized enzyme. In the presence of GSH, MSeI may con-
stitute a redox cycle involving a catalytic reduction of H2O2
and thereby mimics the glutathione peroxidase (GPx) activ-
ity in vitro. In addition, MSeI eﬀectively inhibits the LPO-
catalyzed iodination of L-tyrosine and the inhibition could
be completely recovered by increasing the H2O2 concentra-
tion.Thesestudiesrevealthatthedegradationoftheintracel-
lular H2O2 by the selenium analogues of antithyroid drugs
may be beneﬁcial to the thyroid gland as these compounds
may act as antioxidants and protect thyroid cells from ox-
idative damage. In addition to its antioxidant activity, MSeI
reacts with I2 to produce novel ionic diselenides containing
iodide or polyiodide anions, which might be eﬀective inter-
mediates in the inhibition of thyroid hormones. However,
further studies with TPO are required to derive some ﬁrm
conclusions regarding the mode of action of the antithyroid
drugs.Ourfutureworkwillfocusonthedesignandsynthesis
of novel sulfur and selenium compounds and study of their
antithyroid and antioxidant activities.
ACKNOWLEDGMENT
This study was supported by the Department of Science and
Technology (DST), New Delhi, India.
REFERENCES
[1] Taurog A. Hormone synthesis: thyroid iodine. In: Braverman
LE, Utiger RD, eds. Werner and Ingbar’s the Thyroid. Philadel-
phia, Pa: Lippincott Williams & Wilkins; 1991:51–97.
[2] Taurog A, Dorris M, Doerge DR. Evidence for a radical mech-
anism in peroxidase-catalyzed coupling. 1. Steady-state exper-
iments with various peroxidases. Archives of Biochemistry and
Biophysics. 1994;315(1):82–89.
[3] Doerge DR, Taurog A, Dorris ML. Evidence for a radi-
cal mechanism in peroxidase-catalyzed coupling. II. Single
turnover experiments with horseradish peroxidase. Archives of
Biochemistry and Biophysics. 1994;315(1):90–99.
[4] Doerge DR, Divi RL. Porphyrin π-cation and protein radicals
in peroxidase catalysis and inhibition by anti-thyroid chemi-
cals. Xenobiotica. 1995;25(7):761–767.
[5] Taurog A, Dorris ML, Doerge DR. Mechanism of simultane-
ous iodination and coupling catalyzed by thyroid peroxidase.
Archives of Biochemistry and Biophysics. 1996;330(1):24–32.
[6] Behne D, Kyriakopoulos A, Meinhold H, K¨ ohrle J. Identiﬁ-
cation of type I iodothyronine 5
￿-deiodinase as a selenoen-
zyme. Biochemical and Biophysical Research Communications.
1990;173(3):1143–1149.
[7] Berry MJ, Banu L, Larsen PR. Type I iodothyronine
deiodinase is a selenocysteine-containing enzyme. Nature.
1991;349(6308):438–440.
[8] Berry MJ, Kieﬀer JD, Harney JW, Larsen PR. Selenocysteine
confers the biochemical properties characteristic of the type
I iodothyronine deiodinase. Journal of Biological Chemistry.
1991;266(22):14155–14158.
[9] K¨ ohrle J. Thyroid hormone deiodination in target tissues-a
regulatory role for the trace element selenium? Experimental
and Clinical Endocrinology. 1994;102(2):63–89.
[10] Larsen PR, Berry MJ. Nutritional and hormonal regulation
of thyroid hormone deiodinases. Annual Review of Nutrition.
1995;15:323–352.
[11] St. Germain DL, Galton VA. The deiodinase family of seleno-
proteins. Thyroid. 1997;7(4):655–668.
[12] K¨ ohrle J. The trace element selenium and the thyroid gland.
Biochimie. 1999;81(5):527–533.
[13] Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Bio-
chemistry, cellular and molecular biology, and physiological
roles of the iodothyronine selenodeiodinases. Endocrine Re-
views. 2002;23(1):38–89.
[14] K¨ ohrle J. Iodothyronine deiodinases. Methods in Enzymology.
2002;347:125–167.
[15] K¨ ohrle J. Selenium and the control of thyroid hormone
metabolism. Thyroid. 2005;15(8):841–853.
[16] K¨ ohrle J, Jakob F, Contempr´ e B, Dumont JE. Selenium,
the thyroid, and the endocrine system. Endocrine Reviews.
2005;26(7):944–984.
[17] Leonard JL, Visser TJ. Biochemistry of deiodination. In: Hen-
nemann G, ed. Thyroid Hormone Metabolism. New York, NY:
Marcel Dekker; 1986:189–229.
[18] Goswami A, Rosenberg IN. Stimulation of iodothyronine
outer ring monodeiodinase by dihydrolipoamide. Endocrinol-
ogy. 1983;112(4):1180–1187.
[19] Buxeraud J, Absil A-C, Claude J, Raby C, Catanzano G,
Beck C. Antithyroid agents: structure-activity relationship.
II. Interpretation of mechanism of action by complexation
of charge transfer. European Journal of Medicinal Chemistry.
1985;20(1):43–50.8 Bioinorganic Chemistry and Applications
[20] Raby C, Lagorce J-F, Jambut-Absil A-C, Buxeraud J, Catan-
zano G. The mechanism of action of synthetic antithyroid
drugs: iodine complexation during oxidation of iodide. En-
docrinology. 1990;126(3):1683–1691.
[21] Basosi R, Niccolai N, Rossi C. Coordination behaviour of an-
tithyroid drugs against the Fe(I)(NO)2 group in solution: ESR
and FT-NMR study. Biophysical Chemistry. 1978;8(1):61–69.
[22] du Mont W-W, Mugesh G, Wismach C, Jones PG. Reactions
of organoselenenyl iodides with thiouracil drugs: an enzyme
mimetic study on the inhibition of iodothyronine deiodinase.
Angewandte Chemie. International Edition. 2001;40(13):2486–
2489.
[23] Roy G, Mugesh G. Chemistry in thyroid gland: iodothyro-
nine deiodinases and anti-thyroid drugs. Phosphorus, Sulfur
and Silicon and the Related Elements. 2005;180(3-4):891–902.
[24] Roy G, Sarma BK, Phadnis PP, Mugesh G. Selenium-
containing enzymes in mammals: chemical perspectives. Jour-
nal of Chemical Sciences. 2005;117(4):287–303.
[25] VisserTJ,KapteinE,Aboul-EneinHY.Selenouracilderivatives
are potent inhibitors of the selenoenzyme type I iodothyro-
nine deiodinase. Biochemical and Biophysical Research Com-
munications. 1992;189(3):1362–1367.
[26] Aboul-Enein HY, Awad AA, Al-Andis NM. Synthesis and
the antiperoxidase activity of seleno analogues of the an-
tithyroid drug propylthiouracil. Journal of Enzyme Inhibition.
1993;7(2):147–150.
[27] Taurog A, Dorris ML, Guziec LJ, Guziec FS Jr. The selenium
analog of methimazole. Measurement of its inhibitory eﬀect
on type I 5
￿-deiodinase and of its antithyroid activity. Bio-
chemical Pharmacology. 1994;48(7):1447–1453.
[28] Guziec LJ, Guziec FS Jr. A directed metalation route to the se-
lenium analog of methimazole. Journal of Organic Chemistry.
1994;59(16):4691–4692.
[29] Taurog A, Dorris ML, Hu W-X, Guziec FS Jr. The selenium
analogof6-propylthiouracil.Measurementofitsinhibitoryef-
fect on type I iodothyronine deiodinase and of its antithyroid
activity. Biochemical Pharmacology. 1995;49(5):701–709.
[30] Roy G, Nethaji M, Mugesh G. Biomimetic studies on anti-
thyroid drugs and thyroid hormone synthesis. J o u r n a lo ft h e
American Chemical Society. 2004;126(9):2712–2713.
[31] Roy G, Mugesh G. Anti-thyroid drugs and thyroid hormone
synthesis: eﬀect of methimazole derivatives on peroxidase-
catalyzed reactions. Journal of the American Chemical Society.
2005;127(43):15207–15217.
[32] Taurog A, Dorris ML, Lamas L. Comparison of
lactoperoxidase- and thyroid peroxidase-catalyzed iodi-
nation and coupling. Endocrinology. 1974;94(5):1286–1294.
[33] Childs RE, Bardsley WG. The steady-state kinetics of perox-
idase with 2, 2
￿-azino-di-(3-ethyl-benzthiazoline-6-sulphonic
acid)aschromogen.TheBiochemicalJournal.1975;145(1):93–
103.
[34] Laurence C, El Ghomari MJ, Le Questel J-Y, Berthelot M,
Mokhlisse R. Structure and molecular interactions of antithy-
roid drugs. Part 3. Methimazole: a diiodine sponge. Journal
of the Chemical Society, Perkin Transactions 2. 1998;(7):1545–
1552.
[35] Roy G, Das D, Mugesh G. Bioinorganic chemistry as-
pects of the inhibition of thyroid hormone biosynthesis by
anti-hyperthyroid drugs. Inorganica Chimica Acta. In press.
http://dx.doi.org/10.1016/j.ica.2006.07.052.
[36] Engler H, Taurog A, Luthy C, Dorris ML. Reversible and irre-
versible inhibition of thyroid peroxidase-catalyzed iodination
by thioureylene drugs. Endocrinology. 1983;112(1):86–95.
[37] Taurog A. The mechanism of action of the thioureylene an-
tithyroid drugs. Endocrinology. 1976;98(4):1031–1046.
[38] Nogimori T, Braverman LE, Taurog A, Fang S-L, Wright G,
Emerson CH. A new class of propylthiouracil analogs: com-
parison of 5
￿-deiodinase inhibition and antithyroid activity.
Endocrinology. 1986;118(4):1598–1605.
[39] Taurog A, Dorris ML, Guziec FS Jr. Metabolism of 35S- and
14C-labeled 1-methyl-2-mercaptoimidazole in vitro and in
vivo. Endocrinology. 1989;124(1):30–39.
[40] Doerge DR. Oxygenation of organosulfur compounds by
peroxidases: evidence of an electron transfer mechanism
for lactoperoxidase. Archives of Biochemistry and Biophysics.
1986;244(2):678–685.
[41] Kobayashi S, Nakano M, Goto T, Kimura T, Schaap AP. An ev-
idence of the peroxidase-dependent oxygen transfer from hy-
drogen peroxide to sulﬁdes. Biochemical and Biophysical Re-
search Communications. 1986;135(1):166–171.
[42] Doerge DR. Mechanism-based inhibition of lactoperoxi-
dase by thiocarbamide goitrogens. Biochemistry. 1986;25(16):
4724–4728.
[43] Doerge DR, Pitz GL, Root DP. Organosulfur oxygenation and
suicide inactivation of lactoperoxidase. Biochemical Pharma-
cology. 1987;36(6):972–974.
[44] Doerge DR, Takazawa RS. Mechanism of thyroid peroxidase
inhibition by ethylenethiourea. Chemical Research in Toxicol-
ogy. 1990;3(2):98–101.
[45] Doerge DR, Cooray NM, Brewster ME. Peroxidase-catalyzed
S-oxygenation: mechanism of oxygen transfer for lactoperoxi-
dase. Biochemistry. 1991;30(37):8960–8964.
[46] Mugesh G, du Mont W-W, Sies H. Chemistry of biologically
important synthetic organoselenium compounds. Chemical
Reviews. 2001;101(7):2125–2179.
[47] Bj¨ orkman U, Ekholm R. Hydrogen peroxide degradation and
glutathione peroxidase activity in cultures of thyroid cells.
Molecular and Cellular Endocrinology. 1995;111(1):99–107.
[48] Ekholm R, Bj¨ orkman U. Glutathione peroxidase degrades in-
tracellular hydrogen peroxide and thereby inhibits intracellu-
lar protein iodination in thyroid epithelium. Endocrinology.
1997;138(7):2871–2878.
[49] Roy G, Nethaji M, Mugesh G. Interaction of anti-thyroid
drugs with iodine: the isolation of two unusual ionic com-
pounds derived from Se-methimazole. Organic and Biomolec-
ular Chemistry. 2006;4(15):2883–2887.
[50] Cooper DS. Antithyroid drugs. The New England Journal of
Medicine. 2005;352(9):905–917.
[51] Inabe T, Matsunago Y. Physical properties and constitu-
tion of the 5,6:11,12- bis(epidithio)naphthacene-iodine com-
plexes (TTT-In). Bulletin of the Chemical Society of Japan.
1978;51(10):2813–2816.
[52] Matsunago Y, Suzuki Y. Electrical and optical properties of the
iodine complexes of phenoxazine, phenoselenazine, and ben-
zophenothiazines. Bulletin of the Chemical Society of Japan.
1972;45(11):3375–3379.
[53] Sano M, Ohno K, Akamatu H. Thermoelectric power of the
iodine complexes of aromatic diamines and thiazines. Bulletin
of the Chemical Society of Japan. 1971;44(12):3269–3271.
[54] Murata K, Tokumoto M, Anjai H, et al. Superconductivity
with the onset at 8-K in the organic conductor beta-(BEDT-
TTF)2I3 underpressure.JournalofthePhysicalSocietyofJapan.
1985;54(4):1236–1239.
[55] Aragoni MC, Arca M, Demartin F, et al. Anti-thyroid drug
methimazole: X-ray characterization of two novel ionic disul-
ﬁdes obtained from its chemical oxidation by I2. J o u r n a lo ft h e
American Chemical Society. 2002;124(17):4538–4539.G. Roy and G. Mugesh 9
[56] Antoniadis CD, Corban GJ, Hadjikakou SK, et al. Synthe-
sis and characterization of (PTU)I2 (PTU = 6-n-propyl-2-
thiouracil) and (CMBZT)I2 (CMBZT = 5-chloro-2-mercap-
tobenzothiazole)andpossibleimplicationsforthemechanism
of action of anti-thyroid drugs. European Journal of Inorganic
Chemistry. 2003;2003(8):1635–1640.
[57] Aragoni MC, Arca M, Demartin F, et al. DFT calcula-
tions, structural and spectroscopic studies on the products
formed between IBr and N,N
￿-dimethylbenzoiimdazole-
2(3H)-thione and -2(3H)-selone. Dalton Transactions.
2005;(13):2252–2258.
[58] Corban GJ, Hadjikakou SK, Hadjiliadis N, et al. Synthe-
sis, structural characterization, and computational studies of
novel diiodine adducts with the heterocyclic thioamides N-
methylbenzothiazole-2-thione and benzimidazole-2-thione:
implications with the mechanism of action of antithyroid
drugs. Inorganic Chemistry. 2005;44(23):8617–8627.
[59] Antoniadis CD, Hadjikakou SK, Hadjiliadis N, Papakyriakou
A, Baril M, Butler IS. Synthesis and structures of Se analogues
of the antithyroid drug 6-n-propyl-2-thiouracil and its alkyl
derivatives: formation of dimeric Se-Se compounds and de-
selenation reactions of charge-transfer adducts of diiodine.
Chemistry - A European Journal. 2006;12(26):6888–6897.
[ 6 0 ]V i s s e rT J ,v a nO v e r m e e r e nE ,F e k k e sD ,D o c t e rR ,H e n -
nemann G. Inhibition of iodothyronine 5
￿-deiodinase by
thioureylenes; structure—activity relationship. FEBS Letters.
1979;103(2):314–318.
[61] Freeman F, Ziller JW, Po HN, Keindl MC. Reactions of
imidazole-2-thiones with molecular iodine and the struc-
tures of two crystalline modiﬁcations of the 1:1 1,3-
dimethylimidazole-2-thione-diiodine charge-transfer com-
plex (C5H8I2N2S). Journal of the American Chemical Society.
1988;110(8):2586–2591.
[62] Bigoli F, Deplano P, Devillanova FA, et al. Reaction of
imidazole-2-selone derivatives with diiodine-synthesis, struc-
tural and spectroscopic characterization of the adduct 1,1
￿-
bis(3-methyl-4-imidazolin-2-selone)methane bis(diiodine)
and of the 1st examples of I-Se-I hypervalent seleniumcom-
pounds- 1,3-dimethyl-4-imidazolin-2-ylium diiodo selena-
nide and 1,2-bis(3-methyl- 4-imidazolin-2-ylium diiodo sel-
enanide)-ethane bis(dichloromethane). Gazzetta Chimica
Italiana. 1994;124(11):445–454.
[63] Aragoni MC, Arca M, Blake AJ, et al. 1,2-Bis(3-methyl-
imidazolin-2-ylium iodobromoselenanide)ethane: oxidative
addition of IBr at the Se atom of a > C = Se Group. Ange-
wandte Chemie International Edition. 2001;40(22):4229–4232.
[64] Williams DJ, Fawcett-Brown MR, Raye RR, et al. Synthe-
sis, characterization, and X-ray crystallographic structure of
1,3- dimeihyl-2 (3H)-imidazoleselone. Heteroatom Chemistry.
1993;4(4):409–414.
[65] du Mont W-W, Martens von Salzen A, Ruthe F, et al. Tunning
selenium—iodine contacts: from secondary soft-soft interac-
tions to covalent bonds. Journal of Organometallic Chemistry.
2001;623(1-2):14–28.
[ 6 6 ]D e p l a n oP ,F e r r a r oJ R ,M e r c u r iM L ,T r o g uE F .S t r u c t u r a la n d
Raman spectroscopic studies as complementary tools in eluci-
dating the nature of the bonding in polyiodides and in donor-
I2 adducts. Coordination Chemistry Reviews. 1999;188(1):71–
95.